Observational studyMedicina (Kaunas, Lithuania)2025
Efficacy and Safety of First-Line Nivolumab Plus Ipilimumab in Patients with Postoperative Recurrent and Inoperable Non-Small Cell Lung Cancer: A Real-World Retrospective Observational Study.
Yuhei Kurata et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.